The Protective Effect of Epigallocatechin-3-Gallate on Paraquat-induced Haemolysis

Moses, Kevin; Pepple, D.J.; Singh, Parvinder

doi:10.7727/wimj.2014.067

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the polymer on its own appears to have little effect on cells at the low concentrations present in vivo [24]. We also showed here that high concentrations of free or loaded EGCG, or empty NPs did not affect the integrity of red blood cells, again in line with previous studies [54][55][56]. No cytotoxicity of EGCG/AA NPs was detectable in cultured brain GPNT endothelial cells or undifferentiated PC12 neuronal cells.…”

Section: Discussionsupporting

confidence: 91%

Epigallocatechin-3-Gallate PEGylated Poly(Lactic-Co-Glycolic) Acid Nanoparticles Mitigate Striatal Pathology and Motor Deficits in 3-Nitropropionic Acid Intoxicated Mice

Cano

Ettcheto

Espina

et al. 2021

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington’s disease (HD)-like symptoms in mice. Materials & methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Epigallocatechin-3-Gallate PEGylated Poly(Lactic-Co-Glycolic) Acid Nanoparticles Mitigate Striatal Pathology and Motor Deficits in 3-Nitropropionic Acid Intoxicated Mice

Cano

Ettcheto

Espina

et al. 2021

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…Osmotic fragility of the erythrocytes was tested after incubation of RBCs with different concentrations of EGCG (0·03–30 mg/ml) in addition to 30 mg/ml of paraquat for 10 minutes. EGCG (30 mg/ml) significantly ( p < 0·05) reduced the hemolysis of erythrocytes exposed to paraquat 29 .…”

Section: Discussionmentioning

confidence: 95%

Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study

Shiha

Soliman

Elbasiony

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Emergence of new molecules acting directly on the hepatitic C virus (HCV) has improved treatment outcomes. However, there is a risk of selecting viral escape mutants, so a new combination is needed using different inhibitors that target different steps of the HCV infectious cycle. Novel single tablet formulations were developed: Dactavira, composed of sofosbuvir (SOF) 400 mg/daclatisvir (DCV) 60 mg/epigallocatechin gallate (EGCG) 400 mg without ribavirin (RBV); and Dactavira plus, which includes RBV 800 mg. A randomized, open-label study was carried out on treatment-naïve non-cirrhotic (Group A, n = 50) and treatment-naïve cirrhotic (Group B, n = 22) patients with genotype 4 HCV infection. Group A was randomly assigned to receive a single daily fixed-dose (Dactavira, n = 25) or the standard of care [SOF 400 mg/DCV 60 mg] (n = 25) daily for 12 weeks. Group B was randomly assigned to receive a single daily fixed-dose (Dactavira plus, n = 11) or the standard of care + RBV 800 mg (n = 11) daily for 12 weeks. Patients receiving Dactavira or Dactavira plus had a significantly more rapid rate of viral load decline as compared to patients receiving the standard of care therapy. Sustained virological response for 12 weeks for Dactavira or Dactavira plus showed no statistically significant difference when compared to the standard of care. Also, they did not affect normal hemoglobin levels (p < 0.001) versus the standard of care. The incorporated EGCG interferes with the viral entry mechanisms, as reported by several investigators, and in turn enhances efficacy and prevents relapse as compared to the standard of care. Also, its antihemeolytic and antifibrotic activities may improve the safety and tolerability of the therapy.

show abstract

“…Consequently, muscle damage is reduced by reversing the metabolic dysfunction of skeletal muscle, making these antioxidants improve the physical performance in mice [ 20 ]. EGCG is known for its efficiency in muscle improvement [ 21 ], as well as decreasing hemolysis of previously induced red blood cell membranes [ 22 , 23 ]. All these properties allow EGCG to be considered as a therapeutic alternative for improving muscle performance in MS patients [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study

et al. 2021

View full text Add to dashboard Cite

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment; while this correlation occurs significantly reversed with muscle percentage before treatment, no correlation is evident after the intervention. These results seem to indicate that Hp could be a marker of muscle status and could be a diagnosis tool after therapeutic intervention in MS patients.

show abstract

The Protective Effect of Epigallocatechin-3-Gallate on Paraquat-induced Haemolysis

Cited by 3 publications

References 10 publications

Epigallocatechin-3-Gallate PEGylated Poly(Lactic-Co-Glycolic) Acid Nanoparticles Mitigate Striatal Pathology and Motor Deficits in 3-Nitropropionic Acid Intoxicated Mice

Epigallocatechin-3-Gallate PEGylated Poly(Lactic-Co-Glycolic) Acid Nanoparticles Mitigate Striatal Pathology and Motor Deficits in 3-Nitropropionic Acid Intoxicated Mice

Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Increase of Beta-Hydroxybutyrate in the Blood: A Pilot Study

Contact Info

Product

Resources

About